Vasogen Inc. About
Vasogen Inc. Vasogen is a leader in the research and commercial
development of immune modulation therapies targeting the chronic inflammation
underlying cardiovascular disorders. Vasogen’s lead product, Celacade™
(immune modulation therapy) is currently in clinical trials for the treatment
of chronic heart
failure and peripheral arterial disease. Celacade™ is designed to target
chronic inflammation by activating the immune system’s physiological anti-inflammatory
response to apoptotic cells. Vasogen is also developing a new class of
phospholipid-based drugs designed to interact with APCs to regulate cytokine
levels and control inflammation. VP025, the first product candidate from
this new class of drugs, is in clinical development for chronic inflammation within
the central nervous system that is associated with a number of neurological diseases,
including Alzheimer's
disease, Parkinson's
disease, and amyotrophic lateral sclerosis (Lou Gehrig's disease). Celacade -- Chronic Heart Failure, Periperheral
Arterial Disease VP025 -- Alzheimer's
disease, Parkinson's disease, and amyotrophic lateral sclerosis (Lou Gehrig's
disease). More
on
Vasogen Key
Statistics for Vasogen
Basic
Chart for Vasogen